
    
      This is a phase 4, randomized, open labelled clinical trial, aiming to assess efficacy and
      safety of 3 ACTs in the treatment of uncomplicated malaria in the Democratic Republic of the
      Congo. Children diagnosed with uncomplicated Plasmodium falciparum uncomplicated malaria will
      be randomized and followed-up during 42 days.
    
  